• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 113 -3 (77) 2025 - Jumaniyоzov H.I., Xakimova G.G. - COMPARATIVE ANALYSIS OF MICRORNA GENE METHYLATION IN VARIOUS MOLECULAR BIOLOGICAL SUBTYPES OF BREAST CANCER

113 -3 (77) 2025 - Jumaniyоzov H.I., Xakimova G.G. - COMPARATIVE ANALYSIS OF MICRORNA GENE METHYLATION IN VARIOUS MOLECULAR BIOLOGICAL SUBTYPES OF BREAST CANCER

COMPARATIVE ANALYSIS OF MICRORNA GENE METHYLATION IN VARIOUS MOLECULAR BIOLOGICAL SUBTYPES OF BREAST CANCER

Jumaniyоzov H.I. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Xakimova G.G. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Talipov O.A. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Salohiddinov H.A. - Tashkent Pediatric Medical Institute

Resume

Purpose: to study the methylation features of microRNA genes (miR-107, -124a-1/2/3, -125b-1, -127, -130b, -137, -203a, -375) in different molecular subtypes of breast cancer. Materials and methods. 70 patients are included in research with a verified diagnosis of breast cancer in the age from 30 to 72 years. Patients with stage II (51.4%) and III (31.4%) are prevailed. Metastases to the lymph nodes were observed in 60%. Invasive ductal carcinoma was detected in 72.8% of cases, invasive lobular carcinoma - 12.8% of cases, other forms of cancer were diagnosed in 14.4% of patients. Moderately differentiated breast cancer was in the majority of patients (74.2%), in 21.4% of cases there was low differentiation, 4.4% of patients had a well-differentiated tumor. Luminal subtype A was found in 27.1% of patients; luminal subtype B Her2-negative - in 18.5% of patients; in 32.8% of cases - luminal subtype B Her2-positive, thrice-negative - in 14.2% and non-luminal Her2 (+) positive subtype - in 7.1% of cases. Methyl-specific polymerase chain reaction (MS-PCR) was used to study the methylation profile of microRNA genes (miR-107, -124a-1/2/3, -125b-1, -127, -130b, -137, -203a, -375 ) in paired images of tumor and histologically unchanged breast tissue. The results were processed with the standard packages STATISTICA, v. 10 and IBM SPSS Statistics, v. 21. Results. It was found that in luminal A subtype breast cancer the frequency of miR-124a-1 and miR-125b-1 methylation in tumor tissue increased by 2.3 (84.2% (n = 16) versus 36.8% (n = 7), p = 0.0069) and 8 times (42.1% (n = 8) versus 15.8% (n = 1), p = 0.0189) respectively in comparison with unchanged breast tissue. At Her2-negative and at Her2-positive lyuminalny In a subtype reliable differences in the frequency of methylation of genes of microrNA miR-124a-1, miR-375 in a tumor and histologically are shown to not changed fabric. The methylation rate of these microRNAs at Her2-positive subtype was 69.5% (16/23) versus 17.3% (4/23), (p = 0.0008) and 43.4% (10/23) versus 13% (3/23), (p = 0.0472), respectively. For Her2 - negative cancer, these values were as follows: 84.6% (11/13) versus 38.4% (5/13), (p = 0.01) and 69.2% (9/13) versus 23% (3/13), (p = 0.01), respectively. A high methylation frequency of miR-124a-3 and miR-125b-1 was established at the Her2-positive B subtype of CMW. At the triple-negative subtype, methylation of miR-125b-1 in tumor tissue was observed in most samples (70% (n = 7), p = 0.0075), and was absent in histologically unchanged tissue. Conclusion: All studied miRs demonstrated increased levels of methylation of the CpG islands of the promoter regions which indicates their potential diagnostic value. The frequency of miR-375 methylation was significantly increased in tumors in the triple-negative subtype in comparison with the luminal B Her2-negative BC subtype. For the Her2-positive luminal B subtype was noted a high percentage of 6 miR methylation.

Key words: Comparative analysis of microRNA gene methylation in different molecular biological subtypes of breast cancer, luminal B Her2-negative subtype of breast cancer.

First page

635

Last page

645

For citation:Jumaniyоzov H.I., Xakimova G.G., Talipov O.A., Salohiddinov H.A. - COMPARATIVE ANALYSIS OF MICRORNA GENE METHYLATION IN VARIOUS MOLECULAR BIOLOGICAL SUBTYPES OF BREAST CANCER//New Day in Medicine 3(77)2025 635-645 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.
  2. Рожкова Н.И., Прокопенко С.П., Мазо М.Л. Диагностика и лечение рака молочной железы: что изменилось за 20 лет. Гинекология Эндокринология. 2018;2(146):35-40.
  3. Рябчиков, Д. А. Роль микроРНК в канцерогенезе и прогнозе злокачественных новообразо-ваний молочной железы. / Рябчиков Д. А., Абдуллаева Э. И., Дудина И. А. и др. // Вестник Российского научного центра рентгенорадиологии Минздрава России 2018;18(2):1-20. До¬ступно по: http://vestnik.rncrr.ru/vestnik/v18/docs/ryabchikov.pdf.
  4. Рябчиков Д.А. МикроРНК и их роль в патогенезе и диагностике рака молочной железы / Рябчиков Д.А, Воротников И. К., Талипов О. А., Чулкова С. В., Логинов В. И., Снеговой А. В.,. Винокуров М. С., Казаков А. М., Хагажеева М. Н., Бердова Ф. К. // Медицинский алфавит. 2020;8(422):12-15. DOI: 10.33667/2078–5631–2020–8(422).
  5. Toiyama Y. Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. / Toiyama Y, Okugawa Y, Tanaka K // Gastroenterology. 2017;153(6):1634-1646.e8, doi: 10.1053/j.gastro.2017.08.037.
  6. Чулкова С.В. Перспективы использования миРНК в качестве диагностических и про-гностических биомаркеров меланомы. / Чулкова С. В., Рябчиков Д. А., Дудина И. А. и др. // Российский биоте¬рапевтический журнал. 2019;18(4):51-56. DOI: 10.17650/1726–9784–2019–18–4–51–56.
  7. Bertoli, G. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. / Bertoli G, Cava C, Castiglioni I. // Theranostics. 2015; 5(10):1122-43. doi: 10.7150/thno.11543.
  8. Бурденный, А.М. Роль гиперметилирования промоторных районов генов RASSF1A и MGMT в развитии рака молочной железы и яичников. / Бурденный А.М., Челышева Д.С., Ходырев Д.С., Пронина И.В., Сельчук В.Ю., Казубская Т.П., Брага Э.А., Логинов В.И. // Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2015;26(2):39-44.
  9. Lujambio, A. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells / Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setién F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., Spiteri I., Das P.P., Caldas C., Miska E., Esteller M. // Cancer Res., 2007;67:1424-1429.
  10. Furuta, M. MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma / Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. // Carcinogenesis, 2010;31:766-776.
  11. Peixoto A. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks Front Oncol / Peixoto A., Relvas-Santos M., Azevedo R., Santos L.L., Ferreira J.A. // 2019;9:е380. doi: 10.3389/fonc.2019.00380
  12. Wang S. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells / Wang S., Huang J., Lyu H., Lee C.K., Tan J., Wang J., Liu B. // Cell Death Dis. 2013;4:e556. doi: 10.1038/cddis.2013.79.
  13. Nie J. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT / Nie J., Jiang H.C., Zhou Y.C., Jiang B., He W.J., Wang Y.F., Dong J. // Biosci Biotechnol Biochem. 2019;83(6):1062-1071. doi: 10.1080/09168451.2019.1584521.
  14. Filippova, E.A. A Group of Hypermethylated miRNA Genes in Breast Cancer and Their Diagnostic Potential / Filippova E.A., Loginov V.I., Pronina I.V., Khodyrev D.S., Burdennyya A.M., Kazubskaya T.P., Braga E.A. //Mol Biol (Mosk). 2019;53(3):421-429. doi: 10.1134/S0026898419030054.
  15. Pronina, I.V. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression / Pronina I.V., Loginov V.I., Burdennyy A.M., Fridman M.V., Senchenko V.N., Kazubskaya T.P., Kushlinskii N.E., Dmitriev A.A., Braga E.A. // Gene. 2017;604:1-8. doi: 10.1016/j.gene.2016.12.018.
  16. Loginov, V.I. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis / Loginov V.I., Pronina I.V., Burdennyy A.M., Filippova E.A., Kazubskaya T.P., Kushlinsky D.N., Utkin D.O., Khodyrev D.S., Kushlinskii N.E., Dmitriev A.A., Braga E.A. // Gene. 2018 Jul 1;662:28-36. doi: 10.1016/j.gene.2018.04.005.
  17. Zhao, X. MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231 / Zhao X., Duan Z., Liu X., Wang B., Wang X., He J., Yao Z., Yang J. // Anat Rec (Hoboken). 2013;296(12):1842-9. doi: 10.1002/ar.22823.
  18. Lou, W. Five miRNAs-mediated PIEZO2 downregulation, accompanied with activation of Hedgehog signaling pathway, predicts poor prognosis of breast cancer / Lou W., Liu J., Ding B., Jin L., Xu L., Li X., Chen J., Fan W. // Aging (Albany NY). 2019 May 6;11(9):2628-2652. doi: 10.18632/aging.101934.
  19. Shui, Y. miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma / Shui Y., Yu X., Duan R., Bao Q., Wu J., Yuan H., Ma C. // Gene. 2017 Apr 20;609:80-87. doi: 10.1016/j.gene.2017.01.036.
  20. Zou Q. MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells / Zou Q. , Yi W., Huang J. at all. // Exp Ther Med.14(2): 1198–1204. doi: 10.3892/etm.2017.4593 PMCID: PMC5525589 PMID: 28810579.

    file

    download